A Phase I Study of Ruxolitinib in Combination With Nilotinib in CML Patients With Evidence of Molecular Disease

Trial Profile

A Phase I Study of Ruxolitinib in Combination With Nilotinib in CML Patients With Evidence of Molecular Disease

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 04 Apr 2017

At a glance

  • Drugs Ruxolitinib (Primary) ; Nilotinib
  • Indications Chronic myeloid leukaemia
  • Focus Adverse reactions
  • Most Recent Events

    • 28 Mar 2017 Planned End Date changed from 1 Apr 2017 to 1 Jan 2018.
    • 06 Dec 2016 Results assessing the maximal tolerated dose (MTD) of ruxolitinib in combination with nilotinib and impact of this combination on BCR-ABL transcript levels, presented at the 58th Annual Meeting and Exposition of the American Society of Hematology
    • 03 Nov 2016 According to Incyte Corporation media release, data will be presented at 58th Annual American Society of Hematology (ASH) meeting 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top